Investors focused on the Medical space have likely heard of AEterna Zentaris (AEZS), but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AEterna Zentaris is one of 842 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AEZS is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for AEZS's full-year earnings has moved 105.40% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, AEZS has gained about 15.99% so far this year. Meanwhile, the Medical sector has returned an average of 0.27% on a year-to-date basis. This shows that AEterna Zentaris is outperforming its peers so far this year.
Looking more specifically, AEZS belongs to the Medical - Biomedical and Genetics industry, which includes 345 individual stocks and currently sits at #58 in the Zacks Industry Rank. This group has gained an average of 6.19% so far this year, so AEZS is performing better in this area.
Investors in the Medical sector will want to keep a close eye on AEZS as it attempts to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AEterna Zentaris Inc. (AEZS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research